GP120

GP120 분자 정보

영어 이름HIV envelope protein gp120시판 약물 수2
임상 약물 수14표적 별명HIV Envelope Protein gp120
최고 연구 개발 단계Approved
영어 이름HIV envelope protein gp120
표적 별명HIV Envelope Protein gp120
시판 약물 수2
임상 약물 수14
최고 연구 개발 단계Approved

제품 문의

GP120분자 배경

Human Immunodeficiency Virus (HIV) can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa. HIV-2 is related to viruses found in sooty mangabeys. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Some of the HIV-1 group M subtypes are known to be more virulent or are resistant to different medications. HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses.Envelope glycoprotein GP120 (or gp120) is the name of the glycoprotein which forms the spikes sticking out of a HIV virus particle. gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. Three gp120s, bound as heterodimers to a transmembrane glycoprotein, gp41, are thought to combine in a trimer to form the envelope spike, which is involved in virus-cell attachment. One half of the molecular weight of gp120 is due to the carbohydrate side chains (the "glyco-" in "glycoprotein"). These are sugar residues which form something almost like a sugar "dome" over the gp120 spikes. This dome prevents gp120 from being recognised by the human immune response. As the HIV virus and the human CD4 cell come together, the gp120 binding site "snaps open" at the last minute.The glycoprotein gp120 is anchored to the viral membrane, or envelope, via non-covalent bonds with the transmembrane glycoprotein, gp41. It is involved in entry into cells by binding to CD4 receptors, particularly helper T-cells. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

GP120분자 별명

GP120,GP120-CN54

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Zinlirvimab10-1074; 10-1074-LS; GS-2872Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
상세
PGT121.414.LSVRC-HIVMAB0107-00-ABPhase 2 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
상세
PGT-121PGT-121Phase 2 ClinicalInternational Aids Vaccine Initiative, Theraclone Sciences Inc, The Scripps Research Institute Inc, The Ragon Institute Of Mgh, Mit And HarvardHIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral
상세
Teropavimab3BNC117-LS-J; 3BNC117-LS; 3BNC117; GS-5423Phase 2 ClinicalThe Rockefeller UniversityHIV Infections; Acquired Immunodeficiency Syndrome
상세
Microbicide monoclonal antibody triple combination (Polymun Scientific Immunobiologische Forschung)Phase 1 ClinicalPolymun Scientific GmbhHIV Infections
상세
PDPHV-201401PDPHV-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
상세
ElipovimabGS-9722Phase 1 ClinicalGilead IncHIV Infections
상세
VRC-HIVAAV070-00-GTAAV8-VRC07Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
상세
Microbicide Monoclonal Antibody Triple Combination (Polymun)Phase 1 ClinicalHIV Infections
상세
env (A, B, C, A/E)/gag DNA Vaccine(NIAID)PD-201401Phase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
상세
Vrc-Hivmab0121-00-AbCAP256J3LSPhase 1 ClinicalNational Institute Of Allergy And Infectious Diseases (Niaid)HIV Infections
상세
FB-1002(Frontier Biotechnologies)FB-1002(前沿生物)Phase 1 ClinicalFrontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of SciencesCoronavirus Disease 2019 (COVID-19)
상세
DS-003DS-003; BMS-793Phase 1 ClinicalBristol-Myers Squibb CompanyHIV Infections; Neoplasms
상세
A-1801A-1801ClinicalWuhan BioRaid Biotechnology Co LtdHIV Infections
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
Radha-108ApprovedBiomix NetworkReceptolHIV Infections
상세
Fostemsavir TromethamineBMS-663068; 97IQ273H4L (UNII code); GSK 3684934; BMS-663068-03; GSK-3684934A; BMS 626529 prodrugApprovedBristol-Myers Squibb CompanyRukobiaUnited StatesHIV InfectionsViiv Healthcare Co2020-07-02HIV Infections
상세
  • 분자 정보
  • 제품 문의
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호